Skip directly to Accessibility Notice

PPH
VanEck Pharmaceutical ETF

Fund Description

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

 
 

  • Fund Ticker

    PPH

  • Exchange

    NASDAQ

  • Inception Date

    12/20/2011

  • ETF Structure

    Physical

  • Administrator

    Van Eck Associates

  • Index Ticker

    MVPPHTR

  • Index Rebalancing

    Quarterly

  as of 03/24/23

  • 30-Day SEC Yield1

    1.84%

  • Total Net Assets

    $369.2M

  • Number of Holdings

    25

  • Options

    Available

  • Gross Expense Ratio2

    0.36%

  • Net Expense Ratio/TER2

    0.36%

  • Distribution Frequency

    Quarterly

  • Next Distribution Date

    03/31/2023
Schedule a Call
How to Buy
Fund FAQ

Key Documents and Links

PPH Fact Sheet
Summary Prospectus
Management Team

Fund Highlights

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

  • Industry Leaders
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Trading Information

  • Fund Ticker

    PPH

  • Index Total Return Ticker

    MVPPHTR

  • NAV

    PPHNV

  • Intraday NAV (IIV)4

    PPHIV

  • Shares Outstanding

    4,888,138

  • Estimated Cash

    PPHEU

  • Total Cash

    PPHTC

  • CUSIP

    92189F692

  • ISIN

    US92189F6925
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.35%

  • Other Expenses

    0.01%

  • Acquired Fund Fees and Expenses

    --

  • Gross Expense Ratio

    0.36%

  • Fee Waivers and
    Expense Reimbursement

    --

  • Net Expense Ratio/TER2

    0.36%

2 Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2024.

Morningstar™ Ratings3 as of 02/28/2023

Category Overall 3 Year 5 Year
Health

3 Morningstar Ratings: When applicable, ratings shown when the ETF is rated three stars or more for any given period. For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its three-, five- and ten-year (if applicable) Morningstar Rating metrics.

© Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Investment Professionals

  • Portfolio Manager and Head of Equity ETFs
  • Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
  • Joined VanEck in 2005
  • CFA charterholder; member of the CFA Society New York
  • BA, Mathematics and Economics, New York University
  • Analyst for Equity ETFs
  • Joined VanEck in 2018
  • Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
  • BS, Finance, Providence College
  • Analyst for Equity ETFs
  • Joined VanEck in 2019
  • Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
  • BS, Accounting, Hunter College

Prices as of 03/24/23

NAV/
Market
Price 		Volume
30-Day Avg./
Last Trading Day 		Daily Change
NAV/
Last Price 		YTD Change NAV/
Last Price 		Premium/
Discount 		30-Day
Median
Bid Ask
Spread 		NAV
Chart
PPH $75.53
$75.55 		165,364
32,192 		$0.83 / +1.11%
$0.87 / +1.16% 		-2.88%
-2.82% 		$0.02
0.03% 		0.03%

Premium/Discount History as of 03/24/23

Calendar Year 2021 1Q 2022 2Q 2022 3Q 2022 4Q 2022 Premium/Discount Charts NAV & Prem/Discount History
PPH Days closed at a premium 146 29 30 26 31
Days closed at NAV 24 9 7 3 3
Days closed at a discount 82 24 25 35 29

Performance History: Average Annual Total Returns* (%)

View All ETFs View All Indices
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) -3.48 -1.62 -2.72 1.45 10.45 7.42 7.91 9.02
PPH (Share Price) -3.43 -1.49 -2.69 1.49 10.47 7.41 7.90 9.11
MVPPHTR (Index) -3.49 -1.75 -2.86 1.24 10.14 7.18 7.79 8.90
Performance Differential (NAV - Index) 0.01 0.13 0.14 0.21 0.31 0.24 0.12 0.12
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) 1.13 16.46 2.64 2.64 8.50 7.50 8.99 9.43
PPH (Share Price) 1.23 16.44 2.60 2.60 8.52 7.51 8.99 9.52
MVPPHTR (Index) 1.15 16.44 2.54 2.54 8.14 7.24 8.89 9.32
Performance Differential (NAV - Index) -0.02 0.02 0.10 0.10 0.36 0.26 0.10 0.11

*Returns less than one year are not annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

The "Net Asset Value" (NAV) of a Fund is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell shares at NAV.

Top 10 Holdings (%) as of 02/28/23

Daily Holdings
Total Holdings: 25
Holding Name
Ticker
Shares
 Market Value
(US$) 		% of Net
Assets
Johnson & Johnson
JNJ US
193,282
29,622,399 7.40
Novo Nordisk A/S
NVO US
164,274
23,160,991 5.79
Abbvie Inc
ABBV US
140,801
21,669,274 5.42
Merck & Co Inc
MRK US
201,854
21,444,969 5.36
Zoetis Inc
ZTS US
123,242
20,581,414 5.14
Haleon Plc
HLN US
2,533,036
19,960,324 4.99
Astrazeneca Plc
AZN US
298,820
19,477,088 4.87
Takeda Pharmaceutical Co Ltd
TAK US
1,260,491
19,348,537 4.84
Eli Lilly & Co
LLY US
62,136
19,337,966 4.83
Novartis Ag
NVS US
224,290
18,867,275 4.72
Top 10 Total (%) 53.36
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%)
as of 02/28/23

Country % of Net Assets
● United States 61.99
● United Kingdom 14.16
● Denmark 5.79
● Japan 4.84
● Switzerland 4.72
● France 4.52
● Israel 3.95
● Other/Cash 0.04

Sector Weightings (%)
as of 02/28/23

Sector % of Net Assets
● Health Care 94.97
● Consumer Staples 4.99
● Other/Cash 0.04

View More Funds

loading...